Human antiglomerular basement membrane autoantibody disease in XenoMouse II

Kevin E.C. Meyers, Juanita Allen, Jeffrey Gehret, Aya Jacobovits, Michael Gallo, Eric G. Neilson, Helmut Hopfer, Raghu Kalluri, Michael P. Madaio

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background. Previous studies have identified regions within α3(IV) collagen in human antiglomerular basement membrane (anti-GBM) disease, however, information pertaining to the nature of the pathogenic human autoantibodies has been limited by a lack of a relevant disease model. Availability of engineered mice that produce antibodies (that is, XenoMouse II™ strains) provides an ideal opportunity to examine the human antibody response. Methods. XenoMouse II™ mice that produce human IgG2 (γ2κ) in response to antigenic challenge were immunized with various forms of α3(IV)NC1 GBM collagen, including native bovine α3(IV) NCl collagen, E. coli expressed r α3(IV)NCl, and mammalian fetal kidney 293 cell expressed r α3(IV)NC1 preparations. The mice were evaluated for autoantibody (Ab) production and nephritis. Results. All immunized XenoMouse II animals produced human anti-GBM Ab associated with proliferative glomerulonephritis, linear IgG deposits along the murine GBM and tubular basement membrane (TBM), C3 deposits (weaker). A fully human mAb (Ig γ2κ), produced from a mouse immunized with native bovine α3(IV)NCl collagen produced basement membrane deposits, nephritis and proteinuria on transfer to normal XenoMouse II. Furthermore, monoclonal antibodies (mAb) shared idiotypic properties with polyclonal autoantibodies derived from patients with anti-GBM disease, supporting a structural relationship among the antibodies. Conclusions. The results further support the importance of α3(IV)NCl collagen in the pathogenesis of anti-GBM disease. Moreover, to our knowledge this is the first demonstration that experimentally induced, pathogenic human autoantibodies result in disease. This new model of anti-GBM disease, therefore, provides the means and unique reagents to both decipher the molecular basis of the human anti-GBM autoantibody response and the opportunity to test specific therapies aimed at modulation of either B cells producing human autoantibodies or the human pathogenic antibodies themselves, in vivo, prior to trial in patients with the spontaneous form of the disease.

Original languageEnglish (US)
Pages (from-to)1666-1673
Number of pages8
JournalKidney International
Volume61
Issue number5
DOIs
StatePublished - Jan 1 2002

Fingerprint

Basement Membrane
Autoantibodies
Collagen
Nephritis
Antibodies
Immunoglobulin G
Monoclonal Antibodies
Glomerulonephritis
Proteinuria
Antibody Formation
B-Lymphocytes
Escherichia coli
Kidney

Keywords

  • Animal model
  • Anti-GBM disease
  • B cell
  • Human autoantibody
  • Mouse model
  • Progressive glomerulonephritis
  • XenoMouse II

ASJC Scopus subject areas

  • Nephrology

Cite this

Meyers, K. E. C., Allen, J., Gehret, J., Jacobovits, A., Gallo, M., Neilson, E. G., ... Madaio, M. P. (2002). Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney International, 61(5), 1666-1673. https://doi.org/10.1046/j.1523-1755.2002.00312.x

Human antiglomerular basement membrane autoantibody disease in XenoMouse II. / Meyers, Kevin E.C.; Allen, Juanita; Gehret, Jeffrey; Jacobovits, Aya; Gallo, Michael; Neilson, Eric G.; Hopfer, Helmut; Kalluri, Raghu; Madaio, Michael P.

In: Kidney International, Vol. 61, No. 5, 01.01.2002, p. 1666-1673.

Research output: Contribution to journalArticle

Meyers, KEC, Allen, J, Gehret, J, Jacobovits, A, Gallo, M, Neilson, EG, Hopfer, H, Kalluri, R & Madaio, MP 2002, 'Human antiglomerular basement membrane autoantibody disease in XenoMouse II', Kidney International, vol. 61, no. 5, pp. 1666-1673. https://doi.org/10.1046/j.1523-1755.2002.00312.x
Meyers KEC, Allen J, Gehret J, Jacobovits A, Gallo M, Neilson EG et al. Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney International. 2002 Jan 1;61(5):1666-1673. https://doi.org/10.1046/j.1523-1755.2002.00312.x
Meyers, Kevin E.C. ; Allen, Juanita ; Gehret, Jeffrey ; Jacobovits, Aya ; Gallo, Michael ; Neilson, Eric G. ; Hopfer, Helmut ; Kalluri, Raghu ; Madaio, Michael P. / Human antiglomerular basement membrane autoantibody disease in XenoMouse II. In: Kidney International. 2002 ; Vol. 61, No. 5. pp. 1666-1673.
@article{516ac3df135c488ca0b8931df9eb1c28,
title = "Human antiglomerular basement membrane autoantibody disease in XenoMouse II",
abstract = "Background. Previous studies have identified regions within α3(IV) collagen in human antiglomerular basement membrane (anti-GBM) disease, however, information pertaining to the nature of the pathogenic human autoantibodies has been limited by a lack of a relevant disease model. Availability of engineered mice that produce antibodies (that is, XenoMouse II™ strains) provides an ideal opportunity to examine the human antibody response. Methods. XenoMouse II™ mice that produce human IgG2 (γ2κ) in response to antigenic challenge were immunized with various forms of α3(IV)NC1 GBM collagen, including native bovine α3(IV) NCl collagen, E. coli expressed r α3(IV)NCl, and mammalian fetal kidney 293 cell expressed r α3(IV)NC1 preparations. The mice were evaluated for autoantibody (Ab) production and nephritis. Results. All immunized XenoMouse II animals produced human anti-GBM Ab associated with proliferative glomerulonephritis, linear IgG deposits along the murine GBM and tubular basement membrane (TBM), C3 deposits (weaker). A fully human mAb (Ig γ2κ), produced from a mouse immunized with native bovine α3(IV)NCl collagen produced basement membrane deposits, nephritis and proteinuria on transfer to normal XenoMouse II. Furthermore, monoclonal antibodies (mAb) shared idiotypic properties with polyclonal autoantibodies derived from patients with anti-GBM disease, supporting a structural relationship among the antibodies. Conclusions. The results further support the importance of α3(IV)NCl collagen in the pathogenesis of anti-GBM disease. Moreover, to our knowledge this is the first demonstration that experimentally induced, pathogenic human autoantibodies result in disease. This new model of anti-GBM disease, therefore, provides the means and unique reagents to both decipher the molecular basis of the human anti-GBM autoantibody response and the opportunity to test specific therapies aimed at modulation of either B cells producing human autoantibodies or the human pathogenic antibodies themselves, in vivo, prior to trial in patients with the spontaneous form of the disease.",
keywords = "Animal model, Anti-GBM disease, B cell, Human autoantibody, Mouse model, Progressive glomerulonephritis, XenoMouse II",
author = "Meyers, {Kevin E.C.} and Juanita Allen and Jeffrey Gehret and Aya Jacobovits and Michael Gallo and Neilson, {Eric G.} and Helmut Hopfer and Raghu Kalluri and Madaio, {Michael P.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1046/j.1523-1755.2002.00312.x",
language = "English (US)",
volume = "61",
pages = "1666--1673",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Human antiglomerular basement membrane autoantibody disease in XenoMouse II

AU - Meyers, Kevin E.C.

AU - Allen, Juanita

AU - Gehret, Jeffrey

AU - Jacobovits, Aya

AU - Gallo, Michael

AU - Neilson, Eric G.

AU - Hopfer, Helmut

AU - Kalluri, Raghu

AU - Madaio, Michael P.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background. Previous studies have identified regions within α3(IV) collagen in human antiglomerular basement membrane (anti-GBM) disease, however, information pertaining to the nature of the pathogenic human autoantibodies has been limited by a lack of a relevant disease model. Availability of engineered mice that produce antibodies (that is, XenoMouse II™ strains) provides an ideal opportunity to examine the human antibody response. Methods. XenoMouse II™ mice that produce human IgG2 (γ2κ) in response to antigenic challenge were immunized with various forms of α3(IV)NC1 GBM collagen, including native bovine α3(IV) NCl collagen, E. coli expressed r α3(IV)NCl, and mammalian fetal kidney 293 cell expressed r α3(IV)NC1 preparations. The mice were evaluated for autoantibody (Ab) production and nephritis. Results. All immunized XenoMouse II animals produced human anti-GBM Ab associated with proliferative glomerulonephritis, linear IgG deposits along the murine GBM and tubular basement membrane (TBM), C3 deposits (weaker). A fully human mAb (Ig γ2κ), produced from a mouse immunized with native bovine α3(IV)NCl collagen produced basement membrane deposits, nephritis and proteinuria on transfer to normal XenoMouse II. Furthermore, monoclonal antibodies (mAb) shared idiotypic properties with polyclonal autoantibodies derived from patients with anti-GBM disease, supporting a structural relationship among the antibodies. Conclusions. The results further support the importance of α3(IV)NCl collagen in the pathogenesis of anti-GBM disease. Moreover, to our knowledge this is the first demonstration that experimentally induced, pathogenic human autoantibodies result in disease. This new model of anti-GBM disease, therefore, provides the means and unique reagents to both decipher the molecular basis of the human anti-GBM autoantibody response and the opportunity to test specific therapies aimed at modulation of either B cells producing human autoantibodies or the human pathogenic antibodies themselves, in vivo, prior to trial in patients with the spontaneous form of the disease.

AB - Background. Previous studies have identified regions within α3(IV) collagen in human antiglomerular basement membrane (anti-GBM) disease, however, information pertaining to the nature of the pathogenic human autoantibodies has been limited by a lack of a relevant disease model. Availability of engineered mice that produce antibodies (that is, XenoMouse II™ strains) provides an ideal opportunity to examine the human antibody response. Methods. XenoMouse II™ mice that produce human IgG2 (γ2κ) in response to antigenic challenge were immunized with various forms of α3(IV)NC1 GBM collagen, including native bovine α3(IV) NCl collagen, E. coli expressed r α3(IV)NCl, and mammalian fetal kidney 293 cell expressed r α3(IV)NC1 preparations. The mice were evaluated for autoantibody (Ab) production and nephritis. Results. All immunized XenoMouse II animals produced human anti-GBM Ab associated with proliferative glomerulonephritis, linear IgG deposits along the murine GBM and tubular basement membrane (TBM), C3 deposits (weaker). A fully human mAb (Ig γ2κ), produced from a mouse immunized with native bovine α3(IV)NCl collagen produced basement membrane deposits, nephritis and proteinuria on transfer to normal XenoMouse II. Furthermore, monoclonal antibodies (mAb) shared idiotypic properties with polyclonal autoantibodies derived from patients with anti-GBM disease, supporting a structural relationship among the antibodies. Conclusions. The results further support the importance of α3(IV)NCl collagen in the pathogenesis of anti-GBM disease. Moreover, to our knowledge this is the first demonstration that experimentally induced, pathogenic human autoantibodies result in disease. This new model of anti-GBM disease, therefore, provides the means and unique reagents to both decipher the molecular basis of the human anti-GBM autoantibody response and the opportunity to test specific therapies aimed at modulation of either B cells producing human autoantibodies or the human pathogenic antibodies themselves, in vivo, prior to trial in patients with the spontaneous form of the disease.

KW - Animal model

KW - Anti-GBM disease

KW - B cell

KW - Human autoantibody

KW - Mouse model

KW - Progressive glomerulonephritis

KW - XenoMouse II

UR - http://www.scopus.com/inward/record.url?scp=0036237034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036237034&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2002.00312.x

DO - 10.1046/j.1523-1755.2002.00312.x

M3 - Article

C2 - 11967016

AN - SCOPUS:0036237034

VL - 61

SP - 1666

EP - 1673

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -